Arisan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel oral therapeutics for emerging infectious diseases and metabolic disorders.
Arisan is advancing multiple small-molecule programs through a highly capital-efficient model supported by non-dilutive government funding to advance medical countermeasures against emerging viral threats. Our Ebola virus disease and Lassa fever programs target two high-priority viral hemorrhagic fevers with significant global health and national security implications.
U.S. Government Validation
In parallel, the company is advancing the potential application of a clinical-stage small-molecule platform in cardiometabolic disorders, including hypertriglyceridemia, visceral adiposity, metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), and obesity-related conditions.
Arisan's mission is to identify significant unmet medical needs and develop innovative therapeutic solutions that improve public health, strengthen global preparedness, and create meaningful value for patients, partners, and stakeholders.